Machado Evelyn Oliveira, Taboada Giselle F, Neto Leonardo Vieira, Haute Flávia R van, Corrêa Lívia L, Balarini Giovanna A, Shrank Yolanda, Goulart Marcio, Gadelha Mônica R
Endocrinology Unit, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro (HUCFF-UFRJ), Rua Nascimento Silva, 555 apt: 101, CEP: 22421-020 Rio de Janeiro (RJ), Brazil.
Endocrinology Unit, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro (HUCFF-UFRJ), Rua Nascimento Silva, 555 apt: 101, CEP: 22421-020 Rio de Janeiro (RJ), Brazil; Diabetes Unit, Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione do Rio de Janeiro (IEDE-RJ), Brazil.
Growth Horm IGF Res. 2008 Oct;18(5):389-393. doi: 10.1016/j.ghir.2008.02.001. Epub 2008 Mar 17.
Acromegalic patients are considered "discordant" if their insulin-like growth factor type I (IGF-I) levels are increased for their age with "safe" growth hormone (GH) levels or if their IGF-I levels are normal for their age with "unsafe" GH levels. The prevalence of discordance in acromegalics has been described to vary from 9.4% to 39%, and it may be observed at diagnosis or during the follow up.
To evaluate the prevalence of discordant levels of IGF-I and GH in our acromegalic population.
Hormonal evaluation was made with an oral glucose tolerance test (OGTT) with the IGF-I being assessed in the basal sample at diagnosis and after 3 months of the adenomectomy. During treatment with octreotide LAR, a GH curve (for the calculation of mean GH) and IGF-I assessment were made every 3 months.
Among the 51 patients evaluated at diagnosis, the prevalence of discordance was 13.7% (7/51). Among the 58 patients evaluated after the surgical procedure, eight (13.8%) had discordant GH and IGF-I levels. Among the 42 patients evaluated during treatment with octreotide LAR, the prevalence of discordant GH and IGF-I levels was 33.3% (14/42). Using 1 microg/L as a cut off level for "safe" GH, the prevalence of discordance was 3.9%, 8.6% and 28.6% at diagnosis, after surgery and during treatment with octreotide LAR, respectively. No difference of sex, age or treatment modality was observed among discordant and concordant patients with any GH cut off level.
We observed a prevalence of discordance similar to that previously described in the literature. We believe that studies evaluating morbidity and mortality in discordant patients are also necessary and will enlighten the true impact of this condition in the follow up of acromegaly.
如果肢端肥大症患者的胰岛素样生长因子I(IGF-I)水平相对于其年龄升高而生长激素(GH)水平“安全”,或者其IGF-I水平相对于其年龄正常而GH水平“不安全”,则被认为是“不一致”的。肢端肥大症患者中不一致的患病率据描述在9.4%至39%之间,并且可能在诊断时或随访期间观察到。
评估我们的肢端肥大症患者群体中IGF-I和GH水平不一致的患病率。
采用口服葡萄糖耐量试验(OGTT)进行激素评估,在诊断时的基础样本以及腺瘤切除术后3个月时评估IGF-I。在使用长效奥曲肽治疗期间,每3个月进行一次GH曲线(用于计算平均GH)和IGF-I评估。
在诊断时评估的51例患者中,不一致的患病率为13.7%(7/51)。在手术后评估的58例患者中,8例(13.8%)的GH和IGF-I水平不一致。在使用长效奥曲肽治疗期间评估的42例患者中,GH和IGF-I水平不一致的患病率为33.3%(14/42)。将1μg/L作为“安全”GH的临界值时,诊断时、手术后和使用长效奥曲肽治疗期间不一致的患病率分别为3.9%、8.6%和28.6%。在任何GH临界值下,不一致和一致的患者之间未观察到性别、年龄或治疗方式的差异。
我们观察到的不一致患病率与先前文献中描述的相似。我们认为,评估不一致患者的发病率和死亡率的研究也是必要的,这将阐明这种情况在肢端肥大症随访中的真正影响。